ATE374788T1 - Polysialinsäurederivate - Google Patents
PolysialinsäurederivateInfo
- Publication number
- ATE374788T1 ATE374788T1 AT04768054T AT04768054T ATE374788T1 AT E374788 T1 ATE374788 T1 AT E374788T1 AT 04768054 T AT04768054 T AT 04768054T AT 04768054 T AT04768054 T AT 04768054T AT E374788 T1 ATE374788 T1 AT E374788T1
- Authority
- AT
- Austria
- Prior art keywords
- polysialic acid
- acid derivatives
- functional group
- instance
- hetero
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 2
- 125000000524 functional group Chemical group 0.000 abstract 2
- MEZJQXVOMGUAMP-UHFFFAOYSA-N 1-(2-methylnaphthalen-1-yl)pyrrole-2,5-dione Chemical group CC1=CC=C2C=CC=CC2=C1N1C(=O)C=CC1=O MEZJQXVOMGUAMP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Farming Of Fish And Shellfish (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03254988 | 2003-08-12 | ||
| EP03255200 | 2003-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE374788T1 true ATE374788T1 (de) | 2007-10-15 |
Family
ID=34196160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04768054T ATE374788T1 (de) | 2003-08-12 | 2004-08-12 | Polysialinsäurederivate |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7691826B2 (de) |
| EP (1) | EP1654289B1 (de) |
| JP (1) | JP2007501888A (de) |
| KR (1) | KR101270692B1 (de) |
| AT (1) | ATE374788T1 (de) |
| DE (1) | DE602004009314T2 (de) |
| ES (1) | ES2294535T3 (de) |
| RU (1) | RU2327703C2 (de) |
| WO (1) | WO2005016973A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| PL229487B1 (pl) | 2002-11-12 | 2018-07-31 | Brigham & Womens Hospital Inc | Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego |
| ES2294535T3 (es) * | 2003-08-12 | 2008-04-01 | Lipoxen Technologies Limited | Derivados del acido polisialico. |
| EP1654290B1 (de) * | 2003-08-12 | 2019-03-13 | Lipoxen Technologies Limited | Sialinsäurederivate für die derivatisierung und konjugation von proteinen |
| US8652334B2 (en) | 2004-08-12 | 2014-02-18 | Lipoxen Technologies Limited | Fractionation of charged polysaccharide |
| EP3184551A1 (de) | 2004-08-12 | 2017-06-28 | Lipoxen Technologies Limited | Sialinsäurederivate |
| US8217154B2 (en) * | 2005-02-23 | 2012-07-10 | Lipoxen Technologies Limited | Activated sialic acid derivatives for protein derivatisation and conjugation |
| EP1877099B1 (de) | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutische konjugate beinhaltend ein lysosomales enzym, polysialinsäure und eine zielkomponente |
| AR060187A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| US8299015B2 (en) * | 2006-07-25 | 2012-10-30 | Lipoxen Technologies Limited | Derivatisation of granulocyte colony-stimulating factor |
| PT2101821E (pt) | 2006-12-15 | 2014-10-03 | Baxter Int | Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo |
| WO2008089403A2 (en) | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharides comprising an aminooxy group and conjugates thereof |
| KR101654375B1 (ko) * | 2007-06-26 | 2016-09-05 | 박스알타 인코퍼레이티드 | 가수분해성 중합체 ｆｍｏｃ-링커 |
| CN102159540B (zh) | 2008-07-21 | 2015-08-12 | 布赖汉姆妇女医院 | 与合成的β-1,6葡糖胺寡糖相关的方法和组合物 |
| EP2316030B1 (de) | 2008-07-25 | 2019-08-21 | Wagner, Richard W. | Proteinscreeningverfahren |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| CN102369023A (zh) | 2008-12-16 | 2012-03-07 | 建新公司 | 寡糖-蛋白缀合物 |
| TW201042257A (en) * | 2009-05-26 | 2010-12-01 | Baxter Int | Detection of antibody that binds to water soluble polymer-modified polypeptides |
| JP5909755B2 (ja) | 2009-07-27 | 2016-04-27 | リポクセン テクノロジーズ リミテッド | 非血液凝固タンパク質の糖ポリシアル酸化 |
| EP3093029A1 (de) * | 2009-07-27 | 2016-11-16 | Baxalta GmbH | Koagulationsproteinkonjugate |
| ES2597954T3 (es) | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
| US8809496B2 (en) | 2009-09-03 | 2014-08-19 | The Noguchi Institute | Production method of 11-sugar sialylglycopeptide |
| RU2522846C2 (ru) * | 2009-11-30 | 2014-07-20 | Российская Федерация, От Имени Которой Выступает Министерство Промышленности И Торговли Российской Федерации | Лекарственный препарат и способ улучшения реологических свойств мокроты и ингаляционное применение такого препарата |
| JP5285022B2 (ja) * | 2010-04-30 | 2013-09-11 | 旭化成株式会社 | 糖ペプチド誘導体及びその製造方法 |
| RU2559522C2 (ru) * | 2010-11-29 | 2015-08-10 | Российская Федерация в лице Министерства промышленности и торговли Российской Федерации | Ингаляционная лекарственная форма полисиалированной дезоксирибонуклеазы i человека и способ ее получения |
| JP5680576B2 (ja) * | 2011-03-03 | 2015-03-04 | 旭化成株式会社 | １１糖シアリルオリゴ糖アスパラギンの製造方法 |
| JP2014520094A (ja) * | 2011-05-27 | 2014-08-21 | バクスター・インターナショナル・インコーポレイテッド | 増加した半減期を有する治療用タンパク質およびそれを調製する方法 |
| WO2015130963A2 (en) | 2014-02-27 | 2015-09-03 | Xenetic Biosciences, Inc. | Compositions and methods for administering insulin or insulin-like protein to the brain |
| WO2018197547A1 (en) | 2017-04-25 | 2018-11-01 | Lipoxen Technologies Limited | Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i |
| WO2018197545A1 (en) | 2017-04-25 | 2018-11-01 | Lipoxen Technologies Limited | Methods of treating multiple myeloma cancers expressing high levels of epo-receptor using psa-epo |
| ES2711669A1 (es) * | 2017-11-02 | 2019-05-06 | Univ Santiago Compostela | Sistemas de liberacion de farmacos de acido polisialico y metodos |
| WO2020099513A1 (en) | 2018-11-13 | 2020-05-22 | Lipoxen Technologies Limited | Glycopolysialylation of blinatumomab |
| US12397014B2 (en) | 2019-02-05 | 2025-08-26 | The Brigham And Women's Hospital, Inc. | Polysaccharide compositions for use in treating filariasis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU675053A1 (ru) | 1977-08-10 | 1979-07-25 | Институт Белка Ан Ссср | 9-Йодацетамидо-метил-антрацен в качестве люминесцентной метки дл белков и белковоподобных полимеров |
| GB9112212D0 (en) * | 1991-06-06 | 1991-07-24 | Gregoriadis Gregory | Pharmaceutical compositions |
| US5329028A (en) * | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| AU685776B2 (en) * | 1993-01-22 | 1998-01-29 | Sloan-Kettering Institute For Cancer Research | Ganglioside-KLH conjugate vaccines with QS-21 |
| US5965532A (en) | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
| DE60116137T2 (de) | 2000-05-16 | 2006-08-24 | Lipoxen Technologies Ltd. | Derivatisierung von proteinen in wässrigem lösungsmittel |
| ES2294535T3 (es) * | 2003-08-12 | 2008-04-01 | Lipoxen Technologies Limited | Derivados del acido polisialico. |
| EP3184551A1 (de) * | 2004-08-12 | 2017-06-28 | Lipoxen Technologies Limited | Sialinsäurederivate |
| US8299015B2 (en) * | 2006-07-25 | 2012-10-30 | Lipoxen Technologies Limited | Derivatisation of granulocyte colony-stimulating factor |
-
2004
- 2004-08-12 ES ES04768054T patent/ES2294535T3/es not_active Expired - Lifetime
- 2004-08-12 JP JP2006523054A patent/JP2007501888A/ja active Pending
- 2004-08-12 EP EP04768054A patent/EP1654289B1/de not_active Expired - Lifetime
- 2004-08-12 US US10/568,111 patent/US7691826B2/en not_active Expired - Lifetime
- 2004-08-12 AT AT04768054T patent/ATE374788T1/de not_active IP Right Cessation
- 2004-08-12 WO PCT/GB2004/003488 patent/WO2005016973A1/en not_active Ceased
- 2004-08-12 KR KR1020067002875A patent/KR101270692B1/ko not_active Expired - Fee Related
- 2004-08-12 RU RU2006107545/04A patent/RU2327703C2/ru active
- 2004-08-12 DE DE602004009314T patent/DE602004009314T2/de not_active Expired - Lifetime
-
2010
- 2010-03-03 US US12/717,073 patent/US20100221808A1/en not_active Abandoned
-
2012
- 2012-10-11 US US13/650,048 patent/US9102714B2/en not_active Expired - Lifetime
-
2015
- 2015-07-05 US US14/791,468 patent/US9920137B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20060270830A1 (en) | 2006-11-30 |
| RU2327703C2 (ru) | 2008-06-27 |
| US9920137B2 (en) | 2018-03-20 |
| DE602004009314D1 (de) | 2007-11-15 |
| EP1654289A1 (de) | 2006-05-10 |
| US20130144043A1 (en) | 2013-06-06 |
| DE602004009314T2 (de) | 2008-02-07 |
| EP1654289B1 (de) | 2007-10-03 |
| ES2294535T3 (es) | 2008-04-01 |
| US7691826B2 (en) | 2010-04-06 |
| JP2007501888A (ja) | 2007-02-01 |
| WO2005016973A1 (en) | 2005-02-24 |
| US9102714B2 (en) | 2015-08-11 |
| KR20060085329A (ko) | 2006-07-26 |
| RU2006107545A (ru) | 2007-09-27 |
| KR101270692B1 (ko) | 2013-06-03 |
| US20150307633A1 (en) | 2015-10-29 |
| US20100221808A1 (en) | 2010-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE374788T1 (de) | Polysialinsäurederivate | |
| EA200301250A1 (ru) | Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры | |
| DE60321825D1 (de) | Maleinsäureamid polymerderivate und ihre biokonjugate | |
| ATE399177T1 (de) | Derivate therapeutischer peptide | |
| CY1120625T1 (el) | Συνθεσεις και μεθοδοι χορηγησης φαρμακολογικων παραγοντων | |
| CY1120644T1 (el) | Μικροκαψουλες παρατεταμενης αποδεσμευσης με βαση πολυ(λακτιδιο-συν-γλυκολιδιο) που περιεχουν ενα πολυπεπτιδιο και ενα σακχαρο | |
| CY1113537T1 (el) | Οξινα σκευασματα ινσουλινης με βελτιωμενη σταθεροτητα | |
| CY1114132T1 (el) | Γαστροανθεκτικες φαρμακοτεχνικες μορφες που περιεχουν ριφαξιμινη | |
| DK1093383T3 (da) | Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel | |
| BR0010750A (pt) | Peptìdeos insulinotrópicos de longa duração | |
| CY1113353T1 (el) | Φαρμακοτεχνικη μορφη αντι-τνf-αλφα αντισωματος | |
| BRPI0408331A (pt) | conjugado de polipetìdeo fisiologicamente ativo possuindo meia vida útil in vivo prolongada | |
| UA101670C2 (ru) | Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца | |
| CY1112330T1 (el) | Πρωτεϊνες συνδεσης gag | |
| FI20050932A7 (fi) | Heterobifunktionaaliset polymeeriset biokonjugaatit | |
| DE69837095D1 (de) | Fluorierung von proteinen und peptiden für positronemissionstomographie | |
| EP1585756A4 (de) | Verabreichung von sirnas | |
| CY1108418T1 (el) | Φαρμακευτικες συνθεσεις της ερυθροποιητινης | |
| BR0306675A (pt) | Dispositivo para prover um número de produtos | |
| DE602006017667D1 (de) | Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen | |
| BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
| ES2422081T3 (es) | Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales | |
| ES2171086T3 (es) | Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica. | |
| CY1105008T1 (el) | Αντιμικροβιακη ενεργοτητα του πρωτου κατιονικου συγκροτηματος της ανθρωπινης λακτοφερρινης | |
| ITMI20022394A1 (it) | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |